For example, several mTOR inhibitors are currently in clinical trials for use in TSC [140,141], such as the RaRE-TS trial investigating the efficacy of rapamycin in drug-resistant epilepsy associated with TSC [142], the TSC-STEPS trial addressing sirolimus use to delay seizure onset in TSC infants [143], and the PRECISION I trial exploring the efficacy and safety of albumin-bound sirolimus in patients with malignant solid tumors harboring TSC1 or TSC2 alterations [144]. Here, TSC1 is linked to tuberous sclerosis.